The present invention relates to detecting serum anti-FadA antibodies in test samples from a patient. Additionally, aspects of the present invention provide the basis for detection of serum anti-FadA antibody levels from test samples and correlation with various conditions of clinical relevance.

Biomarkers and combinations thereof for determining risk and onset of preeclampsia, methods for their use and for diagnosis, prediction of risk, management, and treatment of preeclampsia in pregnant human females are provided.

The present invention relates to automated methods for isolating fetal cells from a sample, such as a blood sample, derived from a pregnant woman. The isolated fetal cells can be used for identifying genetic abnormalities in the fetal DNA.

Provided are: a composition for diagnosing pre-eclampsia; a kit; a method of diagnosing pre-eclampsia using the same; and a method of providing information on diagnosis of pre-eclampsia. The composition, the kit, and the methods provide the effect of enabling the accurate and sensitive diagnosis of pre-eclampsia in a subject.

Disclosed herein is a method of identifying and/or addressing incipient preeclampsia in a patient-subject by the steps of (a) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a said patient-subject at about 25 weeks of pregnancy or earlier; (b) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a pregnant non-preeclampsia one or more subjects at about 30 weeks of pregnancy or later, wherein said at least one sialyl Lewis antigen assay is for a sialyl Lewis antigen assayed in step (a) is and if more than one subject is assayed, averaging said results; and (c) managing said patient-subject for preeclampsia, if said level of at least one sialyl Lewis antigen of step (a) is at or greater than about 20% above the level of such silalyl Lewis antigen assayed in step (b).

The present invention relates to automated methods for isolating fetal cells from a sample, such as a blood sample, derived from a pregnant woman. The isolated fetal cells can be used for identifying genetic abnormalities in the fetal DNA.

Disclosed are methods and systems using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the detection and/or analysis of progesterone metabolites, such as progesterone sulfates, in biological samples. In some cases, the amount of progesterone sulfate may be used to distinguish whether gestational pruritus of the skin is an early symptom of (ICP) or due to benign pruritus gravidarum.

Compositions and methods for predicting due date and time to birth for a pregnancy with significantly higher accuracy than current clinical methods. The compositions and methods for predicting due date and time to birth for a pregnancy can also identify those pregnancies that will deliver earlier than the due date derived from Last Menstrual Period (LMP) and/or obstetric ultrasonography (US) dating.

The present disclosure relates to a computer-implemented method for predicting a risk of an infant developing bronchopulmonary dysplasia (BPD), the method comprising the steps of: obtaining a dataset, of the infant, comprising a. clinical data; b. lung maturity data; and c. gastric aspirate (GAS) data; analysing said dataset, thereby obtaining an analysed data result; and based on said analysed data result predicting the risk of the infant developing BPD.

This invention relates to the use of biomarker LRG1 as a biomarker for preeclampsia for use from the first trimester. Elevated levels of leucine-rich alpha 2 glycoprotein 1 (LRG1) can predict risk for the future development of preeclampsia or other hypertensive disorders of pregnancy. The predictive test will comprise the measurement of LRG1 protein, peptide fragment, DNA or RNA, from either blood, plasma, serum, urine, saliva or amniotic fluid. The invention provides a method and a test kit to assess the risk of pre-eclampsia in pregnant woman. The method or test can utilise antibodies to measure levels of LGR1 in a sample.